Tarveda Therapeutics is a clinical stage biopharmaceutical company that takes a novel approach to cancer treatment by creating proprietary Pentarins™, which are potent and selective, miniaturized conjugates uniquely designed to drive efficacy through deep and rapid penetration into solid tumors resulting in sustained payload accumulation and cancer cell death. Through our Pentarin platform, we are developing therapeutics to address the limitations of current cancer therapies in solid tumors.

Pentarins effectively penetrate into solid tumors and kill cancer cells with highly selective binding to target proteins on or in tumor cells where they accumulate and hold a potent payload in the cell, leading to tumor cell death.

Tarveda is developing its pipeline of Pentarins to address a wide range of cancers. Our pipeline includes PEN-221, a novel cancer therapeutic that is highly selective for the somatostatin receptor that is in a Phase 1/2a clinical trial. PEN-221 is being developed to treat patients with neuroendocrine cancers including small cell lung cancer. PEN-866 is highly selective for Heat Shock Protein 90 (HSP90) and has demonstrated complete and durable tumor regressions in xenograft models of small-cell lung cancer, pancreatic cancer, ovarian cancer and sarcoma. To see our pipeline of Pentarins, [click here]